ھایدرۆکسی پرۆجێسترۆن ئاستەیت: جیاوازیی نێوان پێداچوونەوەکان

ناوەڕۆکی سڕاو ناوەڕۆکی زیادکراو
Adding 1 book for ویکیپیدیا:سەلماندنیبوون (20211014sim)) #IABot (v2.0.8.2) (GreenC bot
ھێڵی ١:
[[پەڕگە:17-Acetoxyprogesterone.svg|وێنۆک|١٧-ئەسیتۆکسی پرۆجێسترۆن (ھایدرۆکسی پرۆجێسترۆن ئاستەیت)]]
'''ھایدرۆکسی پرۆجێسترۆن ئاستەیت''' ('''OHPA''')، لەژێر ناوی بازرگانی (پرۆدۆکس '''Prodox''') دەفرۆشرێت، دەرمانێکی [[پڕۆجێستۆجین (دەرمان)|پرۆجستینی]] [[دەرمان لە ڕێگەی دەم|کاریگەرە لە ڕێگەی دەمەوە]]، پەیوەندیدارە بە ھایدرۆکسی پرۆجێسترۆن کاپرۆیت کە لە [[پزیشکی]] بۆ [[پزیشکیی ئاژەڵ|پزیشکی ئاژەڵان]] بەکارھاتووە<ref name="Elks2014">{{cite book|author=J. Elks|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA664|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=664–}}</ref><ref name="Springer2013">{{cite book|url=https://books.google.com/books?id=t8GpBgAAQBAJ&pg=PA6|title=Die Gestagene|date=27 November 2013|publisher=Springer-Verlag|isbn=978-3-642-99941-3|pages=6,278}}</ref><ref name="pmid 13475464">{{cite journal|vauthors=DAVIS ME, WIED GL|year=1957|title=17-alpha-HYDROXYPROGESTERONE acetate; an effective progestational substance on oral administration|url=https://archive.org/details/sim_journal-of-clinical-endocrinology-and-metabolism_1957-10_17_10/page/1237|journal=The Journal of Clinical Endocrinology and Metabolism|volume=17|issue=10|pages=1237–44|doi=10.1210/jcem-17-10-1237|pmid=13475464|quote=It is the purpose of this paper to introduce and describe a new steroid for oral administration, 17-a-hydroxyprogesterone acetate*, and to compare it with the most widely used oral substance with progestational properties, 20,21-anhydro-17-/3-hydroxyprogesterone. * Prodox, Upjohn Co. , Kalamazoo, Michigan [...] It was found that 17-a-hydroxyprogesterone acetate has a progestational activity which is at least twice that of anhydrohydroxyprogesterone.}}</ref><ref name="LoboCrosignani2002">{{cite book|author1=Roger Lobo|url=https://books.google.com/books?id=IFoVyqjrywQC&pg=PA91|title=Women's Health and Menopause: New Strategies - Improved Quality of Life|author2=P.G. Crosignani|author3=Rodolfo Paoletti|date=31 October 2002|publisher=Springer Science & Business Media|isbn=978-1-4020-7149-2|pages=91–}}</ref><ref name="StollerMichota2009">{{cite book|author1=James K. Stoller|url=https://books.google.com/books?id=O9F7wtiPWxgC&pg=PA13|title=The Cleveland Clinic Foundation Intensive Review of Internal Medicine|author2=Franklin A. Michota|author3=Brian F. Mandell|publisher=Lippincott Williams & Wilkins|year=2009|isbn=978-0-7817-9079-6|pages=13–}}</ref><ref name="Ravina2011">{{cite book|author=Enrique Ravina|url=https://books.google.com/books?id=iDNy0XxGqT8C&pg=PA194|title=The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs|date=11 January 2011|publisher=John Wiley & Sons|isbn=978-3-527-32669-3|pages=194–}}</ref><ref name="Sneader2005">{{cite book|author=Walter Sneader|url=https://books.google.com/books?id=Cb6BOkj9fK4C&pg=PA204|title=Drug Discovery: A History|date=23 June 2005|publisher=John Wiley & Sons|isbn=978-0-471-89979-2|pages=204–|quote=In 1954, Karl Junkmann of Schering AG reported that the acetylation of the 17-hydroxyl group of ethisterone provided a derivative suitable for formulating in oil for injection intramuscularly as a depot medication.79 There resulted widespread interest in preparing the acetates (and other esters) of various hydroxy-steroids. One such ester, Upjohn's 17-acetoxyprogesterone, provided to be a promising progestogen even though its hydroxy precursor was inactive. Unfortunately, it turned out that no significant prolongation of action was obtained by formulating it in oil. The Upjohn researchers, however, made the unexpected discovery that their acetoxy derivative was orally active, an observation that had been missed by the Schering group, who were primarily interested in the oil solubility of such esters.}}</ref><ref name="Upjohn1978">{{cite book|author=Upjohn Company|url=https://books.google.com/books?id=wPFUAAAAYAAJ|title=Proceedings of the Symposium on Cheque® for Canine Estrus Prevention, Brook Lodge, Augusta, Michigan, March 13-15, 1978|publisher=Upjohn Company|year=1978|page=16|quote=[...] The first product was 17alpha-acetoxyprogesterone4 (Figure 1) marketed under the trade name of Prodox. ® Prodox was introduced in 1960, was designed for oral use and was not a marketing success. The reasons are not clear as to lack of clear success, but one predominant reason was the high cost. For the average size dog, the cost of preventing estrus for a year was approximately $90. In addition, the inconvenience of daily oral administration may have prevented some market acceptance, especially at that cost. In 1963, Upjohn introduced injectable medroxyprogesterone acetate6 (Figure 1) under the trade name of Promone. Injections were to be made every six months, and this procedure was well accepted by both veterinarians and pet owners. However, Promone sales were discontinued in April, 1966 in the United States for basically two reasons. First was a prolonged and unpredictable return to estrus. This appeared to be due to very slow and variable absorption from the injection site. As a result of this variable absorption rate, one would expect a variable return to estrus. Even after [...]}}</ref> بەگوێرەی ڕێپۆرت ھەروەھا لە کۆنترۆلی دووگیانیش بەکارھاتووە<ref name="RudelKinel1972">{{cite book|author1=Harry W. Rudel|url=https://books.google.com/books?id=Nv5sAAAAMAAJ|title=Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents|author2=Fred A. Kinel|date=September 1972|publisher=Pergamon Press|isbn=978-0-08-016812-8|editor1=M. Tausk|volume=II|pages=385–469 <!-- Table on page 401 -->|chapter=Oral Contraceptives. Human Fertility Studies and Side Effects|oclc=278011135}}</ref>{{پڕۆجێستۆجین و دژە پڕۆجێستۆجینەکان}}
 
== سەرچاوەکان ==